3602 POSTER The Number Needed to Treat (NNT) as a Measure of Incremental Drug Benefit: Denosumab Vs. Zoledronic Acid for the Prevention of Skeletal Related Events (SREs) in Castration-Resistant Prostate Cancer (CRPC)

✍ Scribed by G. Dranitsaris; S. Kaura

• Book ID: 117661691
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 39 KB
• Volume: 47
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(11)71199-6